Company

Tarsa Therapeutics

Tarsa Therapeutics developed oral treatments for postmenopausal osteoporosis, including TBRIA™.

About

Founded in 2009 and based in Philadelphia, Tarsa Therapeutics focused on treatments for postmenopausal osteoporosis. Its TBRIA™ product is an oral formulation of calcitonin that underwent the global Phase 3 ORACAL trial. In August 2014, it raised USD 10.00 mn in venture debt from Oxford Finance Corporation and Square 1 Bank.

4Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in